NCI-Supported Clinical Trials for Coronavirus

Clinical trials are research studies that involve people. Through clinical trials, doctors find new ways to improve treatments and the quality of life for people with disease.

NCI supports clinical trials to test promising treatments for patients with coronavirus disease 2019 (COVID-19) and to learn more about the disease's effects on the body. Some of the trials are specifically for patients with cancer. Your doctor can help you decide if a trial is right for you.

Trials 1-25 of 29
1 2 Next >

  • A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed / Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)

    The primary objective of this study is to evaluate the safety and tolerability of TAK-981 as a single agent in participants with advanced or metastatic solid tumors and lymphomas in dose escalation and cancer treatment expansions, and to assess change in acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load within 8 days of TAK-981 administration in COVID expansion.
    Location: 7 locations

  • Best Supportive Care with or without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19 Infection

    This phase III trial compares best supportive care combined with low dose whole lung radiation therapy vs. best supportive care alone in treating patients with COVID-19 infection. Low-dose radiation therapy is a type of radiation treatment in which the total dose of radiation is less than that given in standard radiation therapy. The radiation dose used in this study is unlikely to cause short term side effects other than fatigue and temporary low blood cell count. The addition of low dose whole lung radiation therapy to best supportive care may improve patients' clinical status, the radiographic appearance of lungs and / or the laboratory blood tests.
    Location: 3 locations

  • A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

    This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a 2-part study comprising a Phase 1 safety lead-in (Part 1) that will determine the recommended TL-895 dose for Phase 2 (Part 2). In Part 1, TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles. Up to 3 dose levels will be evaluated. In Part 2, eligible subjects will be randomized in a 1:1 ratio to TL-895 with standard available treatment (SAT), or placebo with SAT. Investigators and Sponsor will be blinded to each subject's assigned study intervention throughout the course of the study.
    Location: 3 locations

  • PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

    This is a Phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • A Study of Hydroxychloroquine Compared to Placebo as Treatment for Patients with COVID-19

    This phase II trial studies how well hydroxychloroquine works in reducing the severity of symptoms in patients with coronavirus disease 2019 (COVID-19). Hydroxychloroquine is approved for the treatment of autoimmune diseases. An autoimmune disease is a condition in which the immune system mistakenly attacks the body. Researchers think that hydroxychloroquine may prevent the immune system from becoming overactive when it is fighting COVID-19. What is learned from this study may help doctors learn more about hydroxychloroquine as a treatment for COVID-19.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Tocilizumab for the Prevention of Respiratory Failure and Death in Patients with Severe COVID-19 Infection

    This phase II trial studies the effect of tocilizumab in preventing respiratory failure and death in patients with severe COVID-19 infection. Part of the complications from the COVID-19 infection may be due to the virus causing damage to the lungs, some of this damage may be caused by an extreme inflammatory reaction produced by the immune system as it tries to fight off the virus. A protein called IL-6 (interleukin 6) plays a major role in this type of inflammation. Tocilizumab may prevent IL-6 from attaching to cells. By blocking IL-6, tocilizumab may prevent damage to the lungs and reduce the need for treatment with a mechanical ventilator. If a patient is already receiving mechanical ventilation to assist with breathing, tocilizumab may improve the patient’s condition enough to allow this treatment to be stopped.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • A Study of N-acetylcysteine in Patients with COVID19 Infection

    This phase II trial identifies the effect of N-acetylcysteine in treating patients who have severe coronavirus disease-2019 (COVID-19) infection that does not respond to treatment (refractory) and are either patients in a critical care unit and / or are connected to a ventilator, or who are not in a critical care unit but require large amounts of supplemental oxygen. Recent studies suggest that the virus that causes COVID-19 may work by suppressing the immune system, which is the body's defense against infections and other diseases. White blood cells called lymphocytes are an important part of this defense, but recently it was found that the number of lymphocytes in a COVID-19 patient’s blood goes down as the infection gets worse and goes up as a patient gets better. N-acetylcysteine has been shown to help increase the number of lymphocytes in the blood when a virus is responsible for lowering it. This trial may help researchers determine whether N-acetylcysteine is effective enough against the virus that causes COVID-19 such that patients could leave the critical care unit or be taken off a ventilator, or could be prevented from needing ventilator support and management in a critical care unit.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients with Moderate and Severe COVID-19

    This phase II trial studies the effect of baricitinib in combination with antiviral therapy for the treatment of patients with moderate or severe coronavirus disease-2019 (COVID-19). Treatment with antiviral medications such as hydroxychloroquine, lopinavir / ritonavir, and / or remdesivir may act against infection caused by the virus responsible for COVID-19. Baricitinib may reduce lung inflammation. Giving baricitinib in combination with antiviral therapy may reduce the risk of the disease from getting worse and may help prevent the need for being placed on a ventilator should the disease worsen compared to antiviral therapy alone.
    Location: 2 locations

  • Low-Dose Radiation Therapy for the Treatment of Storming Cytokines and Unchecked Edema in Patients with COVID-19 Infection, RESCUE 1-19 Study

    This phase I / II trial studies how well low-dose radiation therapy works in treating patients with SARS or pneumonia associated with COVID-19 infection. The purpose of this study is to investigate the use of selectively localized low-dose radiation therapy in reducing pulmonary immuno-toxicity (lung damage) within viral pneumonia infiltrates in critically-ill patients with SARS-COVID-19.
    Location: 2 locations

  • Anti-IL-8 (BMS-986253) for Hospitalized Patients with COVID-19

    This phase II trial investigates how well BMS-986253 works in treating hospitalized patients with severe COVID-19. COVID-19 is a highly contagious respiratory disease caused by the SARS-CoV-2 virus. The primary causes of death in patients infected with SARS-CoV-2 is acute respiratory distress syndrome, which is primarily a process mediated by molecules promoting inflammation that in turn leads to profound lung injury. BMS-986253 is a human monoclonal antibody against the inflammation promoting mediator called interleukin-8 (IL-8), with potential antineoplastic activities. BMS-986253 may help to improve the health condition ofoutcome of COVID-19 patients.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

    Adults who have tested positive for SARS-CoV-2 infection and who do not require supplemental oxygen will receive PUL-042 Inhalation Solution or placebo 3 times over a one week period in addition to their normal care. Subjects will be be followed and assessed for their clinical status over 28 days to see if PUL-042 Inhalation Solution improves the clinical outcome
    Location: M D Anderson Cancer Center, Houston, Texas

  • A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy and to Treat Systemic Inflammation Associated with COVID-19

    This phase II trial studies how well anakinra works in preventing severe decreased brain function (neurotoxicity), a dangerous condition called cytokine release syndrome (CRS) caused by CAR-T cells, or inflammation associated with COVID-19 infection. T cells (a type of immune cells) are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added in the laboratory. The special receptor is called a chimeric antigen receptor (CAR) and this type of modified T cells are called CAR-T cells. Cytokines are proteins that control body’s inflammatory response. In CRS, a large amount of cytokines is released into the blood, which may cause changes in blood pressure and heartbeat, flu-like symptoms (nausea, fever, and chills), and / or affect the way lungs / liver / kidneys work. CAR-T cell therapy may also cause brain-related symptoms (neurotoxicity), such as dizziness, weakness, confusion, difficulty speaking, and / or possible paralysis, and / or coma. Sometimes the immune system can become overactive in fighting the COVID-19 infection (causing a severe inflammatory reaction), and when a person’s immune system gets out of control that person can become very ill. Anakinra works by blocking the inflammatory cytokine, called IL-1 (interleukin-1) that is released into the blood during or shortly after CAR-T cell therapy or during COVID-19 infection, and causes an inflammatory (swelling) reaction. Anakinra may prevent or reverse the severe side effects of CAR-T cell therapy or COVID-19 infection.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection

    The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization and the rate of morbidity and mortality in participants with severe COVID-19 compared to placebo.
    Location: See Clinical

  • Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

    CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Lopinavir / Ritonavir for the Treatment of COVID-19 Positive Patients with Cancer and Immune Suppression in the Last Year

    This phase II trial studies how well lopinavir / ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by COVID-19. Lopinavir / ritonavir may help to lessen or prevent COVID-19 symptoms from getting worse in cancer patients.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

    This phase Ib / II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients with SARS-CoV-2 Infection

    This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substances (cytokines) made by cells of the immune system as a response to SARS-CoV-2 infection. Tocilizumab may help lower the body’s immune response and reduce inflammation. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic

    This phase I trial investigates breathing techniques and meditation for health care workers during COVID-19 pandemic. Yoga is an ancient system of practices used to balance the mind and body through exercise, meditation (focusing thoughts), and control of breathing and emotions. Studies have shown benefit of yoga in healthy volunteers as well as cancer patients. The benefits range from decreasing inflammation to improvement in immune system. Pranayama is a term used to describe breathing techniques that are an integral part of yoga practice. Pranayama and meditation may help manage stress and improve lung health. The goal of this trial is to learn if web-based breathing techniques and meditation help to reduce stress and improve lung health in health care workers dealing with the COVID-19 pandemic.
    Location: M D Anderson Cancer Center, Houston, Texas

  • A Study of Hydroxychloroquine versus Placebo to Prevent COVID-19 Infection in Patients Receiving Radiation Therapy

    This phase II trial studies how well hydroxychloroquine works in preventing infection with the COVID-19 virus in patients receiving radiation therapy. Hydroxychloroquine has been approved for the prevention and treatment of malaria, and the treatment of lupus and rheumatoid arthritis. Receiving radiation therapy may increase the risk of infection with the COVID-19 virus because the patients are in frequent and close contact with healthcare workers and with other patients who may have become infected. Patients receiving treatment for cancer may also have weakened immune system. Giving hydroxychloroquine may help prevent infection with SARS-CoV-2 in patients who are receiving radiation therapy for their cancer.
    Location: 7 locations

  • BCG Vaccine for Health Care Workers as Defense Against COVID 19

    SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmented by infection of healthcare workers (HCW). Strategies to prevent infection and disease severity of HCW are, therefore, desperately needed to safeguard continuous patient care. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in in vitro and in vivo studies, and reported morbidity and mortality reductions as high as 70%. Furthermore, in our preliminary analysis, areas with existing BCG vaccination programs appear to have lower incidence and mortality from COVID191. The investigators hypothesize that BCG vaccination can reduce HCW infection and disease severity during the epidemic phase of SARS-CoV-2.
    Location: M D Anderson Cancer Center, Houston, Texas

  • The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2

    Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days. Subjects will be followed for the incidence and severity of COVID-19 over 28 days. Subjects will be tested for infection with SARS-CoV-2 at the beginning, middle and end of the study.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19)

    This study investigates a new diagnostic test in detecting SARS-CoV-2, the virus that causes the disease COVID-19. This may help to improve testing for COVID-19.
    Location: 2 locations

  • Remote COVID-19 Symptom Tracking and Improved Cancer Symptom Control for Cancer Patients at Home during the Pandemic

    This trial studies the use of an automated telehealth system, Symptom Care at Home (SCH), to assist with the care and monitoring of cancer symptoms and symptoms related to COVID-19 in cancer patients. The continued monitoring and care of cancer patients is important during a time when face-to-face contact is not advised due to a very contagious virus in the community. The SCH application may help improve communication by alerting cancer care providers about patients’ symptom concerns when the patient is at home. By doing this, providers may be able to care for patients remotely so they do not have to come into the clinics unless advised.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • NCI COVID-19 in Cancer Patients, NCCAPS Study

    This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.
    Location: 793 locations

  • Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients with Breast Cancer Undergoing Breast Surgery

    This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast surgery. Post-mastectomy reconstructive patients are at high risk for financial toxicity (adverse effects of escalating health care cost on well-being). The goal of this study is to collect information about financial costs patients may have as a result of surgical treatment for cancer with or without breast reconstruction and to learn if COVID-19 affects patient costs of breast reconstruction. This may help researchers demonstrate the financial consequences of undergoing breast surgery.
    Location: 4 locations

1 2 Next >